3 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Synta Pharmaceuticals Corp.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Docetaxel, Ganetespib - Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB | Phase 3 | Terminated | Synta Pharmaceuticals Corp. | 696 | 2013-04-01 | 2016-07-01 |
| Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Docetaxel, Combination of ganetespib and docetaxel - Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2 / Phase 3 | Terminated | Synta Pharmaceuticals Corp. | 385 | 2011-05-01 | 2015-11-05 |
| Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma Elesclomol (STA-4783), Paclitaxel - Melanoma | Phase 3 | Terminated | Synta Pharmaceuticals Corp. | 630 | 2007-08-01 | 2014-03-04 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1)
Docetaxel (2) · Paclitaxel (1) · STA 9090 (1) · elesclomol (1)
Canada (3) · Germany (3) · Romania (3) · Spain (3) · United Kingdom (3) · United States (3) · Belgium (2) · Bosnia and Herzegovina (2) · Croatia (2) · Czechia (2) · Poland (2) · Russia (2) · Serbia (2) · Australia (1) · Austria (1)